Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

BridgeBio Pharma, Inc. - Common Stock (NQ:BBIO)

67.33 +1.76 (+2.68%)
Streaming Delayed Price Updated: 2:10 PM EDT, Sep 28, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about BridgeBio Pharma, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
BridgeBio Pharma Eyes Four Global Launches by 2027 as Attruby Nears Blockbuster Status ↗
BridgeBio Pharma (NASDAQ:BBIO) expects 2027 to be a transformative year as it expands from one commercial product to four globally launched therapies, President and CFO Thomas Trimarchi said during a... 
Via MarketBeat
News headline image
BridgeBio (BBIO) Q2 2026 Earnings Call Transcript ↗
Attruby revenue surged to $222.4 million as three pipeline programs entered regulatory review. 
Via The Motley Fool
Topics Earnings
News headline image
Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗
Yes, Alnylam has had some bad news. But the bad news isn't as horrible as many think. 
Via The Motley Fool
BridgeBio Pharma (NASDAQ:BBIO) Flashes Perfect Technical Score and Tight Breakout Setup ↗
Via Chartmill
BridgeBio Pharma (NASDAQ:BBIO) Q1 2026 Revenue Beat Driven by Attruby Sales Surge, Shares Jump ↗
Via Chartmill
BridgeBio Pharma Inc (NASDAQ:BBIO) Posts Q4 Revenue Beat on Heart Drug Surge, Eyes Multiple 2026 NDA Submissions ↗
Via Chartmill
News headline image
BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher. ↗
The company clearly has a winner on its hands with the recently approved Attruby. 
Via The Motley Fool
News headline image
BridgeBio Pharma Q2 Earnings Call Highlights ↗
BridgeBio Pharma (NASDAQ:BBIO) reported continued growth for its ATTR cardiomyopathy treatment Attruby in the second quarter of 2026, while advancing three late-stage programs into regulatory review... 
Via MarketBeat
Topics Earnings
News headline image
1 Top Wall Street Analyst Thinks This Stock Could Soar 95% Over the Next 12 Months. Here's Why I Agree. ↗
Rapid commercial momentum could justify Wall Street's bullish outlook. 
Via The Motley Fool
News headline image
The Phase 3 Failure That Sent Biotech Winners and Losers in Opposite Directions ↗
Wainua missed its Phase 3 endpoint, hitting Ionis Pharmaceuticals hard while AstraZeneca absorbed the blow easily, boosting rivals BridgeBio, Pfizer and Alnylam Pharmaceuticals. 
Via MarketBeat
There are notable gap-ups and gap-downs in today's session. ↗
Via Chartmill
News headline image
Wall Street Thinks This Biotech Stock Can Soar 45%. Here's Why Analysts Are Right. ↗
Analysts have given Alnylam Pharmaceuticals an average price target of $436. 
Via The Motley Fool
News headline image
BridgeBio Pharma Touts Attruby Blockbuster Path, 3 Potential Pipeline Launches ↗
BridgeBio Pharma (NASDAQ:BBIO) executives used a BofA healthcare conference appearance in Las Vegas to reiterate confidence in the commercial trajectory of Attruby and outline expectations for three... 
Via MarketBeat
News headline image
BridgeBio (BBIO) Q1 2026 Earnings Transcript ↗
BridgeBio (BBIO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
BridgeBio (BBIO) Q2 2025 Earnings Transcript ↗
BridgeBio (BBIO) Q2 2025 Earnings Transcript 
Via The Motley Fool
News headline image
Ascendis Pharma Completes Strategic Trifecta with U.S. Launch of YUVIWEL and Seven-Year Orphan Exclusivity
In a move that signals a transformative shift from a clinical-stage biotech to a commercial-market leader, Ascendis Pharma (NASDAQ: ASND) officially launched its third major product, YUVIWEL... 
Via MarketMinute
Topics Economy
News headline image
BridgeBio Pharma Inc (NASDAQ:BBIO) Shows High Technical and Setup Ratings Ahead of Potential Breakout ↗
BridgeBio Pharma (BBIO) shows a strong technical uptrend with a high-quality consolidation pattern, signaling a potential breakout opportunity for traders. 
Via Chartmill
News headline image
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript ↗
BridgeBio (BBIO) Q4 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
MoonLake Stock Soars As Biotech Fund Reloads, Takeover Chatter Ignites ↗
Optimism also grew around FDA momentum for its palmoplantar pustulosis drug ahead of MoonLake’s Feb. 23 investor day. 
Via Stocktwits
News headline image
Biotech Exit: $26 Million Arcellx Sale Follows Tepid Stock Performance and Kelonia Competition ↗
Arcellx develops cell-based immunotherapies targeting cancer, with a lead candidate in early-stage trials for multiple myeloma. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Cogent Biosciences Stock Up 346% as Fund Builds $29 Million Stake After November Phase 3 Breakthrough ↗
Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Fund Discloses $35 Million Biotech Buy Amid Staggering 830% Terns Stock Surge ↗
This clinical-stage biotech develops therapies for NASH and obesity, advancing a diverse pipeline of small-molecule drug candidates. 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Alnylam Pharmaceuticals (ALNY): The RNAi Pioneer’s 2026 Breakout and the Battle for Cardiovascular Dominance
As of February 12, 2026, Alnylam Pharmaceuticals (NASDAQ: ALNY) has officially transcended its status as a high-potential biotech and entered the pantheon of global pharmaceutical powerhouses. Known as... 
Via Finterra
Topics Economy Intellectual Property
News headline image
BBIO Stock Surges 17% Pre-Market Today – What’s Fueling The Rally? ↗
The company reported positive results from its PROPEL 3 study of its experimental oral therapy, infigratinib, in children with achondroplasia, a genetic form of dwarfism. 
Via Stocktwits
News headline image
The Sound of Silence: Revolution Medicines Plummets 17% as M&A Hopes Evaporate
The high-stakes world of biotechnology faced a jarring reality check on January 26, 2026, as shares of Revolution Medicines (Nasdaq: RVMD) cratered by 17%. The sharp decline came as the speculative... 
Via MarketMinute
Topics ETFs Government Initial Public Offering
News headline image
BioMarin’s $4.8 Billion Amicus Acquisition: A Strategic Pivot to Rare Disease Dominance
In a move that has sent shockwaves through the biotechnology sector, BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced on December 19, 2025, that it has entered into a definitive agreement to... 
Via MarketMinute
Topics Economy Intellectual Property
News headline image
The RNAi Powerhouse: A Deep Dive into Alnylam Pharmaceuticals’ Path to the S&P 500
As the calendar turns to 2026, Alnylam Pharmaceuticals (Nasdaq: ALNY) stands at the threshold of a new era. Once a speculative pioneer in the arcane world of RNA interference (RNAi), the... 
Via PredictStreet
Topics Economy Intellectual Property Stocks
News headline image
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? ↗
Is Rapport Therapeutics Stock a Buy After Investment Firm Cormorant Raised Its Stake Over $60 Million? 
Via The Motley Fool
Topics Regulatory Compliance
News headline image
How BridgeBio, A Top 4% Stock, Is Lining Up Dominos On Its Triple-Digit Sprint ↗
Shares of BridgeBio Pharma are nearing a record high as the small biotech company takes on drug behemoths Pfizer and Alnylam. 
Via Investor's Business Daily
News headline image
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript ↗
BridgeBio (BBIO) Q3 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.